Gennova’s mRNA-based COVID-19 vaccine gets approval for Phase 2/3 clinical trials


PTI, Aug 24, 2021, 5:12 PM IST

New Delhi: India’s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday.

The Pune-based biotechnology company had submitted the interim clinical data of the vaccine”s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said.

The Vaccine Subject Expert Committee (SEC) reviewed the interim Phase 1 data and found that the HGCO19 vaccine was safe, tolerable, and immunogenic in the participants of the study.

“Gennova submitted the proposed Phase 2 and Phase 3 study entitled ”A Prospective, Multicentre, Randomised, Active-controlled, Observer-blind, Phase 2 study seamlessly followed by a Phase 3 study to evaluate the Safety, Tolerability, and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects” which was approved by the office of the DCG(I), CDSCO,” the DBT said.

The study will be conducted in the country at approximately 10-15 sites in Phase 2 and 22-27 sites in Phase 3. Gennova plans to use the DBT-ICMR clinical trial network sites for this study, it said.

Gennova”s mRNA-based COVID-19 vaccine development programme was partly funded by the DBT under Ind CEPI in June 2020.

Later on, the DBT further supported the programme under ”Mission COVID Suraksha – The Indian COVID-19 Vaccine Development Mission”, implemented by BIRAC.

Renu Swarup, Secretary of DBT and Chairperson of Biotechnology Industrial Research Assistance Council (BIRAC), said this is an important milestone in the country”s indigenous vaccine development mission, and it positions India on the global map for novel vaccine development.

Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd, said, “After establishing the safety of our mRNA-based COVID-19 vaccine candidate HGCO19 in Phase 1 clinical trial, Gennova”s focus is to start Phase 2/3 pivotal clinical trial.

“In parallel, Gennova is investing in scaling up its manufacturing capacity to cater to the nation”s vaccine requirement,” he said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Kinnigoli: Truck carrying red stone collides with Auto-Rickshaw; driver injured

UP govt to install 150,000 toilets for Maha Kumbh, set up paying guest facilities

Kavoor Police arrest two notorious cattle thieves

Udupi: Unidentified body found near Bailkere’s Vidhyodaya School

Sexual harassment case cannot be closed on basis of compromise between parties: SC

MLC Ivan D’Souza defends CM Siddaramaiah’s Lokayukta appearance, criticizes BJP’s ‘Drama’ claims

Ranji Trophy: Shreyas Iyer’s majestic 233 puts Mumbai in complete command against Odisha

Related Articles More

Felling of trees: What is being done to restore Delhi Ridge? SC asks DDA

UP govt to install 150,000 toilets for Maha Kumbh, set up paying guest facilities

Sexual harassment case cannot be closed on basis of compromise between parties: SC

BJP slams Rahul Gandhi over his recent opinion piece, calls it ‘laughable’

I’m not anti-business, I’m anti-monopoly: Rahul

MUST WATCH

Gho Pooja in Deepavali Festival

Melukote Deepavali

Ganapathi Co-operative Society Ltd

Udayavani Chinnara Banna 2024

Annapoorna Aahar | Food Places In Mysore


Latest Additions

Felling of trees: What is being done to restore Delhi Ridge? SC asks DDA

Kinnigoli: Truck carrying red stone collides with Auto-Rickshaw; driver injured

UP govt to install 150,000 toilets for Maha Kumbh, set up paying guest facilities

Kavoor Police arrest two notorious cattle thieves

Udupi: Unidentified body found near Bailkere’s Vidhyodaya School

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.